Hepatobiliary excretion of berberine

Area of Science:

• Pharmacology
• Pharmacokinetics
• Natural Products

Background:

• Berberine is a bioactive compound from Berberis aristata and Coptis chinensis.
• Understanding berberine's pharmacokinetics and excretion is crucial for its therapeutic use.

Purpose of the Study:

• To investigate the detailed pharmacokinetics of berberine.
• To elucidate the mechanisms of berberine's hepatobiliary excretion.
• To identify berberine's metabolic pathways in the liver.

Main Methods:

• In vivo microdialysis coupled with high-performance liquid chromatography in rats.
• Administration of berberine alone or with inhibitors of P-glycoprotein (cyclosporin A), organic cation transporter (quinidine), cytochrome P450 (SKF-525A), and glucuronidation (probenecid).
• Analysis of berberine concentrations in bile and blood, and identification of metabolites using liquid chromatography/tandem mass spectrometry.

Main Results:

• Berberine demonstrated linear pharmacokinetics within the 10-20 mg/kg dosage range.
• Hepatobiliary excretion occurred against a concentration gradient, suggesting active transport.
• P-glycoprotein and organic cation transporter inhibition significantly reduced berberine's biliary efflux.
• Berberine metabolism involves hepatic phase I demethylation and phase II glucuronidation.
• Phase I metabolism was partially inhibited by SKF-525A, while phase II was unaffected by probenecid.

Conclusions:

• Berberine's hepatobiliary excretion is an active process potentially mediated by P-gp and OCT.
• Berberine undergoes significant hepatic metabolism via phase I and phase II pathways.
• These findings provide insights into berberine's disposition and potential drug interactions.